title: Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.
authors.forename: F
authors.initials: F
authors.lastname: Stagno
authors.forename: P
authors.initials: P
authors.lastname: Vigneri
authors.forename: V
authors.initials: V
authors.lastname: Del Fabro
authors.forename: S
authors.initials: S
authors.lastname: Stella
authors.forename: M
authors.initials: M
authors.lastname: Massimino
authors.forename: S
authors.initials: S
authors.lastname: Berretta
authors.forename: A
authors.initials: A
authors.lastname: Cupri
authors.forename: C
authors.initials: C
authors.lastname: Consoli
authors.forename: L
authors.initials: L
authors.lastname: Messina
authors.forename: E
authors.initials: E
authors.lastname: Tirrò
authors.forename: A
authors.initials: A
authors.lastname: Messina
authors.forename: F
authors.initials: F
authors.lastname: Di Raimondo
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D000068877:Imatinib Mesylate; D007438:Introns; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib